Published in J Alzheimers Dis on January 01, 2009
Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology (2011) 2.52
Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med (2011) 1.93
Reliability and validity of food frequency questionnaire and nutrient biomarkers in elders with and without mild cognitive impairment. Alzheimer Dis Assoc Disord (2011) 0.93
Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice. Pharmacol Biochem Behav (2009) 0.88
Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction. Biofactors (2012) 0.86
A critical review of vitamin C for the prevention of age-related cognitive decline and Alzheimer's disease. J Alzheimers Dis (2012) 0.86
Sustained choroid plexus function in human elderly and Alzheimer's disease patients. Fluids Barriers CNS (2013) 0.84
Ascorbic acid and the brain: rationale for the use against cognitive decline. Nutrients (2014) 0.82
Scurvy in the Great Irish Famine: evidence of vitamin C deficiency from a mid-19th century skeletal population. Am J Phys Anthropol (2012) 0.82
Vitamin C deficiency in the brain impairs cognition, increases amyloid accumulation and deposition, and oxidative stress in APP/PSEN1 and normally aging mice. ACS Chem Neurosci (2015) 0.81
The influence of micronutrients in cell culture: a reflection on viability and genomic stability. Biomed Res Int (2013) 0.80
Dehydroascorbic Acid Attenuates Ischemic Brain Edema and Neurotoxicity in Cerebral Ischemia: An in vivo Study. Exp Neurobiol (2015) 0.79
Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease. Metab Brain Dis (2012) 0.78
Biomarkers for Alzheimer's disease: showing the way or leading us astray? J Alzheimers Dis (2013) 0.75
Does vitamin C deficiency affect cognitive development and function? Nutrients (2014) 0.75
Vitamin C, Aging and Alzheimer's Disease. Nutrients (2017) 0.75
Vitamin C Status and Cognitive Function: A Systematic Review. Nutrients (2017) 0.75
Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer's disease and a novel protective role for ascorbate. Free Radic Biol Med (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res (1983) 41.26
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest (1977) 4.63
Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A (1989) 4.02
Dietary intake of antioxidants and risk of Alzheimer disease. JAMA (2002) 4.01
Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci (2001) 3.11
Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci (1994) 2.51
Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci (2000) 2.36
Oxidative alterations in Alzheimer's disease. Brain Pathol (1999) 2.21
Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging (2002) 2.06
Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke (1996) 1.60
Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res (2007) 1.54
Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology (2007) 1.53
Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med (2008) 1.38
Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology (1997) 1.27
Micronutrient and urate transport in choroid plexus and kidney: implications for drug therapy. Pharm Res (2006) 1.21
The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages. Neurology (1996) 1.18
Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis (2002) 1.18
Role of the antioxidant ascorbate in hibernation and warming from hibernation. Comp Biochem Physiol C Toxicol Pharmacol (2002) 1.03
Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing (2001) 0.99
Ascorbate concentration in human cerebrospinal fluid (CSF) and serum. Intrathecal accumulation and CSF flow rate. Clin Chim Acta (1993) 0.97
Vitamin homeostasis in the central nervous system. N Engl J Med (1977) 0.94
Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand (1997) 0.91
Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance. J Nutr Health Aging (2002) 0.90
Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain. J Alzheimers Dis (2003) 0.88
Antioxidants and cognitive function. Nutr Rev (2001) 0.82
Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future. Aging health (2008) 0.80
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
A new proposed guidance system for beverage consumption in the United States. Am J Clin Nutr (2006) 4.12
Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr (2003) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet (2002) 3.03
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr (2006) 2.72
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Intelligent Systems For Assessing Aging Changes: home-based, unobtrusive, and continuous assessment of aging. J Gerontol B Psychol Sci Soc Sci (2011) 2.71
Anthocyanins, phenolics, and antioxidant capacity in diverse small fruits: vaccinium, rubus, and ribes. J Agric Food Chem (2002) 2.70
Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol (2002) 2.70
Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA (2003) 2.69
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc (2008) 2.13
A pilot whole systems clinical trial of traditional Chinese medicine and naturopathic medicine for the treatment of temporomandibular disorders. J Altern Complement Med (2008) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Unobtrusive assessment of activity patterns associated with mild cognitive impairment. Alzheimers Dement (2008) 1.95
Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci U S A (2007) 1.95
Uric acid as a CNS antioxidant. J Alzheimers Dis (2010) 1.93
Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med (2006) 1.85
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol (2002) 1.79
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
An electronic pillbox for continuous monitoring of medication adherence. Conf Proc IEEE Eng Med Biol Soc (2006) 1.72
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry (2003) 1.70
Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology (2012) 1.66
Algorithm for complementary and alternative medicine practice and research in type 2 diabetes. J Altern Complement Med (2007) 1.64
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke (2004) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res (2002) 1.63
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Cognitive impairment risk: white matter hyperintensity progression matters. Neurology (2009) 1.46
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis (2008) 1.40
Echinacea purpurea for prevention of upper respiratory tract infections in children. J Altern Complement Med (2005) 1.40
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 1.39
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 1.39
Parkinson's disease is associated with hippocampal atrophy. Mov Disord (2003) 1.37
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One (2011) 1.32
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics (2007) 1.31
Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol (2003) 1.30
Mind-body interventions: applications in neurology. Neurology (2008) 1.30
Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med (2010) 1.27
Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health (2009) 1.26
Tracking cognitive functioning over time: ten-year longitudinal data from a community-based study. Appl Neuropsychol (2003) 1.26
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Obesity and oxidative stress: a direct link to CVD? Arterioscler Thromb Vasc Biol (2003) 1.25
Genetic deficiency of NADPH oxidase does not diminish, but rather enhances, LPS-induced acute inflammatory responses in vivo. Free Radic Biol Med (2008) 1.23
Physical activity and the risk of dementia in oldest old. J Aging Health (2007) 1.22
Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F-isoprostanes. Anal Biochem (2006) 1.21
Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation (2007) 1.21
Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res (2006) 1.20
Metal-independent production of hydroxyl radicals by halogenated quinones and hydrogen peroxide: an ESR spin trapping study. Free Radic Biol Med (2002) 1.20
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Greater orbital prefrontal volume selectively predicts worse working memory performance in older adults. Cereb Cortex (2002) 1.17
Retirement patterns from career employment. Gerontologist (2006) 1.16
Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging (2010) 1.16
One walk a year to 1000 within a year: continuous in-home unobtrusive gait assessment of older adults. Gait Posture (2011) 1.16
Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly. J Sleep Res (2005) 1.13
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis (2013) 1.12
High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum (2007) 1.12
Relevance of apple polyphenols as antioxidants in human plasma: contrasting in vitro and in vivo effects. Free Radic Biol Med (2004) 1.10
L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis (2010) 1.10
A study of medication-taking and unobtrusive, intelligent reminding. Telemed J E Health (2009) 1.07
Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis (2004) 1.07
Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J (2005) 1.06
Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. Free Radic Biol Med (2011) 1.06
Salivary cortisol awakening response in mild Alzheimer disease, caregivers, and noncaregivers. Alzheimer Dis Assoc Disord (2008) 1.05
Neuropathologic basis of age-associated brain atrophy. JAMA Neurol (2013) 1.05